This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
Trade Parameters
Technical Observations – For
Technical Observations – Against
Shares have momentum thanks to positive drug news on Farxiga (cardiovascular) and Imfinzi (cancer). Deutsche Bank (26 Sept) says Astra has enough positive data for label expansion for Farxiga and Imfinzi results should help cement it as a new standard-of-care in patients suffering from stage 3 inoperable lung cancer.
Risks to AstraZeneca shares include poor results in November, any negative drug trial updates, a sustained market rally that favours risk assets rather than defensive/non-cyclicals and, of course, broker downgrades.
rokers/analysts are bullish on the shares with only 16% suggesting Sell. This is supported by 54% of broker price targets suggesting upside from current levels, to a consensus target of 6123p, which is right in-line with short-term target of revisiting August highs of 6121p.
Next Event: Q3 Results, 8 November
Latest Broker 12-Month Consensus: 62% Buy, 22% Hold, 16% Sell (full breakdown on request)
Source: DowJones Newswires, Reuters News, Bloomberg or Company Press releases
| 1wk | 1m | 3m | 6m | 1yr | 2yr | 3yr | 4yr | 5yr | |
| Perf % | 4.9 | -0.1 | 12.8 | 23.5 | 20.2 | 15.3 | 35.7 | 33.3 | 81.4 |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research